Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesGains from Sales and DivestituresGains from Sales and DivestituresNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Maze Therapeutics (MAZE) Cash from Operations (2024 - 2025)

Maze Therapeutics has reported Cash from Operations over the past 2 years, most recently at 27730000.0 for Q4 2025.

  • Quarterly Cash from Operations fell 23.51% to 27730000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 111940000.0 through Dec 2025, down 247.38% year-over-year, with the annual reading at 111940000.0 for FY2025, 247.38% down from the prior year.
  • Cash from Operations was 27730000.0 for Q4 2025 at Maze Therapeutics, down from 24642000.0 in the prior quarter.
  • Over five years, Cash from Operations peaked at 145048000.0 in Q2 2024 and troughed at 30052000.0 in Q2 2025.